| | |
| |||||||
 أنت تتصفح الموقع كزائر، للحصول على مساعدة في التسجيل أو استرجاع كلمة المرور اضغط هنا. |
 |
| | LinkBack | أدوات الموضوع |
|
#1
Nov, 01 2008, 19:39
| |||
| |||
| Small Outbreak of Zyvox-Resistant MRSA in Spanish Hospital Small Outbreak of Zyvox-Resistant MRSA in Spanish Hospital MRSA is a bacterium that causes infections in different parts of the body, including the skin, bloodstream, lungs, and urinary tract. About 94,000 Americans get serious MRSA infections each year and 19,000 die, according to the CDC. Miguel Sanchez, MD, of the Hospital Clinico San Carlos in Madrid, says the 12 cases of Zyvox-resistant MRSA occurred in the hospital's intensive care unit during a two-month period this spring. Half of the patients died. Nine patients had the same mutation of resistant MRSA, which suggests the superbug spread from patient to patient, Sanchez says. The outbreak was controlled by ensuring that health care workers donned gowns, gloves, and other protective gear in the ICU and by slashing the use of Zyvox, according to Sanchez. Resistance can develop when a bug is exposed to, but not completely wiped out, by an antibiotic. Fortunately, all of the strains were susceptible to treatment with antibiotics other than Zyvox, he says. No new cases have been reported since the end of June. In other research presented at the meeting, the experimental antibiotic ceftaroline cured skin infections caused by MRSA in 95% of patients. That was the same success rate observed with the older combination of the antibiotics vancomycin and aztreonam. All the treatments were given intravenously Ceftaroline fights bugs other than MRSA, too. "Most other common pathogens are also killed" by the drug, she tells WebMD. In a second study, the experimental drug PTK 0796 wiped out MRSA infections in 98% of patients, compared with 93% of those treated with Zyvox. There were no serious adverse events associated with use of the new drug, says Robert Arbeit, MD, of Paratek Pharmaceuticals in Boston. Paratek makes the drug and sponsored the research. The study involved 188 people with MRSA who were given either PTK 0796 or Zyvox intravenously for four days and then orally for about six days. The antibiotic Iclaprim also proved effective against skin infections caused by MRSA and other bugs, other research showed. It cured infections in 93% of patients vs. 98% of those given Zyvox. The intravenous drug, which is currently awaiting FDA review, was studied in about 1,000 patients. Manufacturer Arpida AG of Reinach, Switzerland, funded the work. http://www.webmd.com/news/20081027/small-outbreak-of-zyvox-resistant-mrsa?src=RSS_PUBLIC  |
| قال العضو التالي أسمه شكراً لك يا Aziz على هذه المشاركة المفيدة: | ||
|
| Bookmarks |
| أدوات الموضوع | |
| |
المواضيع المشابهة | ||||
| الموضوع | مبتدئ الموضوع | المنتدى | الردود | آخر مشاركة |
| !!!A SMALL TRUTH TO MAKE LIFE 100%!!! | BAD_ANGEL_! | اجتماعيات | 5 | Mar, 22 2006 19:43 |
| Risk of Acute Pancreatitis amd Small Gallstones | Philip Hardo | آخر المستجدات الطبية | 0 | Nov, 14 2005 13:17 |
| World Hospital Directory | Philip Hardo | مقهى الملتقى | 1 | Nov, 04 2005 17:38 |
